Reshema Kemps-Polanco
Known title: DirectorCIK: 0002009357
Associated companies
Transaction History
| CRL | ▲ Buy | Grant | 1,438 | $255K | 5/8/2026 | View on chart |
| CRL | ▲ Buy | Grant | 535 | $95K | 5/8/2026 | View on chart |
| CRL | ▲ Buy | Grant | 946 | $128K | 5/21/2025 | View on chart |
| CRL | ▲ Buy | Grant | 630 | $85K | 5/21/2025 | View on chart |
| CRL | ▲ Buy | Grant | 559 | $128K | 5/13/2024 | View on chart |
| CRL | ▲ Buy | Grant | 285 | $65K | 5/13/2024 | View on chart |
| CRL | ▲ Buy | Grant | 170 | $0 | 2/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage
Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.